Cian Healthcare is currently trading at Rs. 25.58, up by 1.68 points or 7.03% from its previous closing of Rs. 23.90 on the BSE.
The scrip opened at Rs. 23.80 and has touched a high and low of Rs. 25.58 and Rs. 23.80 respectively. So far 30000 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 41.10 on 31-May-2023 and a 52 week low of Rs. 13.55 on 22-Aug-2022.
Last one week high and low of the scrip stood at Rs. 25.58 and Rs. 22.10 respectively. The current market cap of the company is Rs. 63.94 crore.
The promoters holding in the company stood at 51.85%, while Non-Institutions held 48.15% stake in the company.
Cian Healthcare has entered into an Agreement with CHI Pharmaceuticals, Nigeria for manufacturing and supply of their products in the country of Nigeria, which is a great success of company to increase Export Business.
The company is excited to embark on this business venture, targeting the Nigerian Market, and taking on the manufacturing responsibilities for CHI Pharma's product range including Supramult, Supramult Plus, GYNOCARE, Spora-Derm, and CHIFENAC, they are shifting this business from korea to its facility in India.
Cian Healthcare is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: